Evidence map›Paper›PMID 27441452›Full record

Trial reportThe American journal of drug and alcohol abuse2017

Long-term follow-up of psilocybin-facilitated smoking cessation.

Matthew W Johnson, Albert Garcia-Romeu, Roland R Griffiths

Erratum issued Registry-linked trialOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of drug and alcohol abuse, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05452772 (5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder), which is not on this map. Cited by 252 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed, 11 pooled it
26.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05452772 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

TypeinterventionalSponsorJohns Hopkins UniversityRan2023 to 2027Enrolled66ConditionsTobacco Use DisorderArmsPsilocybin, Niacin
3 · Its place in the literature

Who cites it

252 citing papers in PubMed, 11 syntheses or guidelines pooled it, 687 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Mechanistic Basis for 5-HTNature communications · 2026
    Article
  16. Review
  17. Article
  18. The working lives of neuronal 5-HTRSC chemical biology · 2026
    Review
  19. Surprising Variability in Tryptamine Profiles ofJournal of fungi (Basel, Switzerland) · 2026
    Article
  20. Ten practical suggestions for setting up a psychedelic study.Journal of psychopharmacology (Oxford, England) · 2026
    Article

192 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Matthew W Johnsona Department of Psychiatry and Behavioral Sciences , Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Albert Garcia-Romeua Department of Psychiatry and Behavioral Sciences , Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Roland R Griffithsa Department of Psychiatry and Behavioral Sciences , Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

HUMAN BEHAVIORAL PHARMACOLOGY OF SUBSTANCE ABUSET32DA007209 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Eric C. Strain, Elise M Weerts · 1985 to 2026
$12.9M
Human Clinical Pharmacology of Emerging Drugs of Abuse (Club Drugs)R01DA003889 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GRIFFITHS, ROLAND R · 1985 to 2017
$7.6M
NIDA NIH HHS R01 DA003889NIDA NIH HHS T32 DA007209
6 · The paper itself

Abstract

backgroundA recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone.

objectivesTo assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration.

methodsThe present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin.

resultsAll 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16-57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives.

conclusionThese results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.

Indexed as

Cognitive Behavioral TherapyCombined Modality TherapyFemaleFollow-Up StudiesHallucinogensHumansMaleMiddle AgedPilot ProjectsPsilocybinSmoking CessationHallucinogensPsilocybinaddictionHallucinogenmystical experiencenicotinepsilocybinpsychedelicsmoking cessationspiritualitytobacco

Identifiers

PMID27441452
PMCPMC5641975
OpenAlexW2506717582

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.